Tonix Pharmaceuticals Holding Corp. Common Stock (TNXP) Stock
NASDAQ · TNXP
Key stats
- Market cap
- $110.11M
- Price / Earnings ratio
- -0.7x
- EPS (TTM)
- -$13.11
- Volume
- Loading
- 52-week high
- $20.69
- 52-week low
- $6.01
Source: third-party data provider, as of October 17, 2026
Compare with TNXP
Recent news

MarketBeat
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears
TNXPSeptember 12, 2026
MarketBeat
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears
TNXP

MarketBeat
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
TNXPAugust 18, 2026
MarketBeat
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
TNXP

MarketBeat
Tonix Pharmaceuticals Q2 Earnings Call Highlights
TNXPAugust 10, 2026
MarketBeat
Tonix Pharmaceuticals Q2 Earnings Call Highlights
TNXP

Stocktwits
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug
TNXPMay 2, 2026
Stocktwits
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug
TNXP
Technical indicators
- RSI 14
- 17.10
- MACD 12/26/9
- -1.40
- EMA 9 of MACD
- -1.21
- MACD histogram
- -0.19
- SMA 50
- $11.06
- Price below SMA 50
- EMA 50
- $10.12
- Price below EMA 50
- SMA 200
- $13.04
- Price below SMA 200
- EMA 200
- $13.15
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2025
16M10M5M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
333M220M110M0
Revenue to Profit
2025$13.1M
Revenue$0.0
Cost of revenue$6.5M
Gross profit$0.0
Operating expenses$-124.0M
Net incomeEarnings
EPS forecast
Actual EPS
$-2.60
Q1FY26
The market is expecting earnings per share of -$2.60 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

MarketBeat
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears
TNXPSeptember 12, 2026
MarketBeat
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears
TNXP

MarketBeat
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
TNXPAugust 18, 2026
MarketBeat
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
TNXP

MarketBeat
Tonix Pharmaceuticals Q2 Earnings Call Highlights
TNXPAugust 10, 2026
MarketBeat
Tonix Pharmaceuticals Q2 Earnings Call Highlights
TNXP

Stocktwits
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug
TNXPMay 2, 2026
Stocktwits
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug
TNXP

Stocktwits
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff
TNXPMarch 27, 2026
Stocktwits
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff
TNXP

Stocktwits
TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print
TNXPMarch 13, 2026
Stocktwits
TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print
TNXP

Stocktwits
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug
TNXPDecember 29, 2025
Stocktwits
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug
TNXP

InvestorPlace
3 Biotech Stocks to Dump Before They Go to Zero
TNXPApril 9, 2024
InvestorPlace
3 Biotech Stocks to Dump Before They Go to Zero
TNXP

PennyStocks
Using News to Find Penny Stocks to Buy: 3 Tips
TNXPJanuary 9, 2023
PennyStocks
Using News to Find Penny Stocks to Buy: 3 Tips
TNXP

InvestorPlace
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
TNXPAugust 17, 2022
InvestorPlace
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
TNXP
About Tonix Pharmaceuticals Holding Corp. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees142
CEODr. Seth Lederman M.D.
IPO DateMay 10, 2012
HeadquartersBerkeley Heights, NJ
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Seth Lederman M.D. | Co-Founder, Interim Chief Medical Officer, President, CEO & Chairman | 1958 |
| Mr. Bradley Saenger CPA | CFO & Treasurer | 1974 |
| Mrs. Jessica Edgar Morris | Chief Operating Officer | — |
| Dr. Gregory M. Sullivan M.D. | Secretary | 1966 |
| Ms. Siobhan Fogarty B.Sc., M.Sc. | Chief Technical Officer | 1969 |
| Ms. Irina Ishak | General Counsel | — |
| Dr. Darryl Rideout Ph.D. | Executive Vice President of Experimental Chemistry | — |
| Dr. Sina Bavari Ph.D. | Executive Vice President of Infectious Disease Research & Development | — |
| Dr. Zeil Rosenberg M.D., M.P.H. | Executive Vice President of Medical | — |
| Mr. Ganesh Kamath | Head of Market Access | — |
Fundamentals
Valuation
Price-to-sales ratio3.77
Price-to-book value0.49
PEG ratio0.00
Profitability
Return on Equity-69.00%
Return on Assets-61.00%
Return on Sales-549.00%
Gross margin (latest quarter)94.81%
EBITDA$-157.54M
Trading
Average volume775,020
Source: third-party data provider, as of October 17, 2026
Technical indicators
- RSI 14
- 17.10
- MACD 12/26/9
- -1.40
- EMA 9 of MACD
- -1.21
- MACD histogram
- -0.19
- SMA 50
- $11.06
- Price below SMA 50
- EMA 50
- $10.12
- Price below EMA 50
- SMA 200
- $13.04
- Price below SMA 200
- EMA 200
- $13.15
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -7.0 | |||||||||||
| 2026 | +4.2 | -18.8 | -1.6 | -5.5 | -9.3 | +3.8 | -19.5 | +32.1 | -30.3 | -30.4 |
Compare stocks
Market cap
$110.11M
-
-
-
Price / Earnings ratio
-0.70
-
-
-
Price / Sales ratio
3.77
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
775,020
-
-
-
Earnings per share
$-13.11
-
-
-



